USPTO serial 85727303
Serial No. 85727303
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCCAULEY, BRENDAN D
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with Serial No. 85727303?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
San Carlos, CA
Redwood City, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
R. Gwen Peterson
R. GWEN PETERSON KILPATRICK TOWNSEND & STOCKTON LLPTWO EMBARCADERO CENTER, 8TH FLOORSAN FRANCISCO, CA 94111-3834UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic preparations and diagnostic kits comprised of buffers and reagents for clinical, medical laboratory, or research use; antibodies for clinical, medical laboratory, or research use; combinations of antibodies for clinical, medical laboratory, or research use; kits containing buffers and reagents for research use | ACTIVE | — |
| 005 | Diagnostic preparations and diagnostic kits comprised of buffers and reagents for medical use; antibodies or antibody sequences for medical use, namely, medical diagnosis; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cancer; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of autoimmune/inflammatory disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cardiovascular disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of neurological disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of metabolic disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of respiratory disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of ophthalmic disease; biologics for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease, cancer, or autoimmune disease in animals; biologics, namely, vaccines for prophylaxis or treatment of infectious disease or cancer in humans; biologics, namely, vaccines for prophylaxis or treatment of infectious disease or cancer in animals; combinations of antibodies or antibody sequences for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cancer; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of autoimmune/inflammatory disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of cardiovascular disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of neurological disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of metabolic disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of respiratory disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of ophthalmic disease; combinations of biologics for medical use, namely, biological preparation for the treatment or prophylaxis of infectious disease, cancer, or autoimmune disease in animals; combinations of biologics, namely, vaccines for prophylaxis or treatment of infectious disease or cancer in humans; combinations of biologics, namely, vaccines for prophylaxis of treatment of infectious disease or cancer in animals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 19, 2017 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 19, 2017 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 22, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 20, 2016 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Nov 10, 2016 | EXT5 | SOU EXTENSION 5 FILED | — |
| Nov 10, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 20, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 19, 2016 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 5, 2016 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 5, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 4, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 4, 2015 | NOAC | CORRECTED NOA E-MAILED | — |
| Dec 3, 2015 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 3, 2015 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 3, 2015 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Dec 3, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 13, 2015 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Nov 13, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Nov 13, 2015 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Nov 13, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 15, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 14, 2015 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 29, 2015 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 29, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 13, 2015 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jan 13, 2015 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 6, 2014 | PAPER RECEIVED | — | |
| Oct 29, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 27, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 27, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 27, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 27, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 22, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 22, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 13, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 18, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 18, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 26, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 10, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 10, 2014 | ALIE | ASSIGNED TO LIE | — |
| Jan 22, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 22, 2014 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 22, 2014 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 22, 2014 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 22, 2014 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 25, 2013 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 25, 2013 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 25, 2013 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 16, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 15, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 15, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 14, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 14, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 14, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 7, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 19, 2012 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Sep 18, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 15, 2012 | NWAP | NEW APPLICATION ENTERED | — |